D C Des Jarlais
Overview
Explore the profile of D C Des Jarlais including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
3276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Des Jarlais D, McKnight C, Arasteh K, Feelemyer J, Ross Z, Cooper H
Harm Reduct J
. 2019 Sep;
16(1):53.
PMID: 31477150
Aims: To identify geographic "hotspots" for potential transmission of HIV and HCV and for drug overdose among persons who use heroin and cocaine in New York City and to examine...
2.
McKnight C, Des Jarlais D
Int J Drug Policy
. 2018 Sep;
60:82-88.
PMID: 30176422
Illicitly manufactured fentanyl (IMF), a category of synthetic opioids 50-100 times more potent than morphine, is increasingly being added to heroin and other drugs in the United States (US). Persons...
3.
Des Jarlais D, Cooper H, Arasteh K, Feelemyer J, McKnight C, Ross Z
PLoS One
. 2018 Mar;
13(3):e0194799.
PMID: 29596464
Objective: We identified potential geographic "hotspots" for drug-injecting transmission of HIV and hepatitis C virus (HCV) among persons who inject drugs (PWID) in New York City. The HIV epidemic among...
4.
Uuskula A, Toompere K, Laisaar K, Rosenthal M, Purjer M, Knellwolf A, et al.
BMJ Open
. 2015 Feb;
5(2):e006591.
PMID: 25649212
Objectives: To assess HIV/AIDS research productivity in the 27 countries of the European Union (EU), and the structural level factors associated with levels of HIV/AIDS research productivity. Methods: A bibliometric...
5.
Des Jarlais D, Arasteh K, McKnight C, Feelemyer J, Hagan H, Cooper H, et al.
AIDS Behav
. 2013 Nov;
18(3):443-51.
PMID: 24271348
Examine long term sexual risk behaviors among persons who inject drugs (PWID) in New York City following implementation of "combined" prevention programming, including condom social marketing. Quantitative interviews and human...
6.
Des Jarlais D, Pinkerton S, Hagan H, Guardino V, Feelemyer J, Cooper H, et al.
Adv Prev Med
. 2013 Jul;
2013:346372.
PMID: 23840957
After 30 years of extensive research on human immunodeficiency virus (HIV) among persons who inject drugs (PWID), we now have a good understanding of the critical issues involved. Following the...
7.
Zeremski M, Makeyeva J, Arasteh K, Des Jarlais D, Talal A
J Viral Hepat
. 2012 Jul;
19(8):554-9.
PMID: 22762139
Noninjection drug use, although recognized as an emerging risk factor for acquisition of other blood-born pathogens, is still unconfirmed as a route of hepatitis C virus (HCV) transmission. Our goal...
8.
Uuskula A, McMahon J, Kals M, Talu A, Abel-Ollo K, Ruutel K, et al.
AIDS Behav
. 2011 Nov;
17(3):879-88.
PMID: 22038080
The HIV epidemic in Estonia, as with other eastern European countries, is currently concentrated among injection drug users (IDUs). Non-IDUs who have IDU sex partners could serve as a potential...
9.
Uuskula A, McMahon J, Raag M, Silm S, Ruutel K, Talu A, et al.
Sex Transm Infect
. 2010 Nov;
86 Suppl 3:iii79-84.
PMID: 21098060
Objectives: HIV/AIDS risk is embodied within multiple levels including structural and social levels. The aim of this study was to assess the effects of neighbourhood characteristics on HIV prevalence among...
10.
Des Jarlais D, Semaan S
J Epidemiol Community Health
. 2009 Feb;
63(3):191-6.
PMID: 19218258
Much has been learned about how to prevent HIV infection among psychoactive drug users in the last 25 years, but, worldwide, the problems of drug-use-related HIV transmission have increased during...